Insulet Co. (NASDAQ:PODD) Insider Charles Alpuche Sells 23,401 Shares

Posted by Defense World Staff on Mar 15th, 2023

Insulet Co. (NASDAQ:PODD – Get Rating) insider Charles Alpuche sold 23,401 shares of the firm’s stock in a transaction on Monday, March 13th. The shares were sold at an average price of $305.15, for a total value of $7,140,815.15. Following the sale, the insider now directly owns 45,584 shares of the company’s stock, valued at $13,909,957.60. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink.

Charles Alpuche also recently made the following trade(s):

On Thursday, March 9th, Charles Alpuche sold 4,000 shares of Insulet stock. The shares were sold at an average price of $290.90, for a total value of $1,163,600.00.
On Tuesday, February 28th, Charles Alpuche sold 4,000 shares of Insulet stock. The shares were sold at an average price of $278.82, for a total value of $1,115,280.00.

Insulet Stock Performance

NASDAQ:PODD opened at $312.77 on Wednesday. The business has a 50 day moving average of $291.62 and a 200 day moving average of $277.41. The company has a market capitalization of $21.75 billion, a price-to-earnings ratio of 5,212.83 and a beta of 0.75. Insulet Co. has a 1-year low of $181.00 and a 1-year high of $320.00. The company has a debt-to-equity ratio of 2.88, a current ratio of 3.60 and a quick ratio of 2.65.

Insulet (NASDAQ:PODD – Get Rating) last released its earnings results on Thursday, February 23rd. The medical instruments supplier reported $0.55 earnings per share for the quarter, topping analysts’ consensus estimates of $0.24 by $0.31. The company had revenue of $369.70 million during the quarter, compared to the consensus estimate of $331.73 million. Insulet had a return on equity of 20.55% and a net margin of 0.35%. Insulet’s quarterly revenue was up 20.1% compared to the same quarter last year. During the same quarter in the previous year, the company posted $0.42 EPS. On average, sell-side analysts predict that Insulet Co. will post 1.26 earnings per share for the current fiscal year.

Institutional Trading of Insulet

A number of hedge funds have recently bought and sold shares of PODD. Moneta Group Investment Advisors LLC lifted its position in Insulet by 101,333.5% in the 4th quarter. Moneta Group Investment Advisors LLC now owns 1,300,377 shares of the medical instruments supplier’s stock worth $382,818,000 after buying an additional 1,299,095 shares during the last quarter. Clearbridge Investments LLC lifted its position in Insulet by 38.8% in the 1st quarter. Clearbridge Investments LLC now owns 1,696,822 shares of the medical instruments supplier’s stock worth $452,016,000 after buying an additional 474,545 shares during the last quarter. Norges Bank purchased a new position in Insulet in the 4th quarter worth approximately $105,275,000. Lord Abbett & CO. LLC increased its stake in Insulet by 652.1% in the 3rd quarter. Lord Abbett & CO. LLC now owns 298,819 shares of the medical instruments supplier’s stock worth $68,549,000 after purchasing an additional 259,089 shares during the period. Finally, Scout Investments Inc. purchased a new position in shares of Insulet during the fourth quarter valued at approximately $45,326,000.

Analysts Set New Price Targets

PODD has been the subject of several research analyst reports. Morgan Stanley raised their target price on Insulet from $320.00 to $325.00 and gave the company an “equal weight” rating in a research report on Friday, February 24th. Barclays lifted their price objective on Insulet from $245.00 to $292.00 in a report on Friday, February 24th. Robert W. Baird lifted their price objective on Insulet from $340.00 to $350.00 and gave the stock an “outperform” rating in a report on Friday, February 24th. Citigroup lifted their price objective on Insulet from $270.00 to $330.00 in a report on Monday, December 12th. Finally, Wolfe Research started coverage on Insulet in a research note on Thursday, January 26th. They issued a “peer perform” rating for the company. Six equities research analysts have rated the stock with a hold rating and six have issued a buy rating to the company. Based on data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $317.82.

Insulet Company Profile

(Get Rating)

Insulet Corp. is a medical device company, which engages in the development, manufacture, and marketing of an insulin infusion system for people with insulin-dependent diabetes. It specializes in diabetes supplies, including the OmniPod System, as well as other diabetes related products and supplies such as blood glucose testing supplies, traditional insulin pumps, pump supplies, and pharmaceuticals.